21 completed. 21 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 21 |
| Phase 2 | 7 | Completed 7 |
Follow Primary Dysautonomias: new trials by email Literature Review of Primary Dysautonomias trials Research Report on Primary Dysautonomias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Levodopa on Cardiovascular Autonomic Function in Parkinson's Disease Autonomic testing on and off levodopa - Parkinson Disease, Orthostatic Hypotension | Phase 2 / Phase 3 | Completed | University of Utah | 40 | 2022-05-11 | 2024-12-05 |
| Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo Buspirone, Placebo - Vertigo, Autonomic Dysfunction | Phase 3 | Completed | Valenta Pharm JSC | 268 | 2022-01-28 | 2022-06-24 |
| A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients DaTSCAN™ Ioflupane (123I) Injection - Parkinsonian Syndrome, Parkinson Disease(PD) | Phase 3 | Completed | GE Healthcare | 172 | 2020-06-28 | 2023-10-16 |
| Study of BHV-3241 in Participants With Multiple System Atrophy Verdiperstat, Placebo - Multiple System Atrophy | Phase 3 | Completed | Biohaven Pharmaceuticals, Inc. | 421 | 2019-07-29 | 2023-09-29 |
| Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure ampreloxetine, Placebo - Symptomatic Neurogenic Orthostatic Hypotension | Phase 3 | Completed | Theravance Biopharma | 195 | 2019-01-24 | 2022-09-14 |
| Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome Ivabradine, Placebo - Postural Orthostatic Tachycardia Syndrome | Phase 3 | Completed | University of California, San Diego | 37 | 2018-02-06 | 2021-06-29 |
| Treatment of Post-SCI Hypotension Midodrine Hydrochloride - Spinal Cord Injury, Autonomic Dysreflexia | Phase 2 / Phase 3 | Completed | James J. Peters Veterans Affairs Medical Center | 66 | 2017-06-01 | 2025-02-21 |
| Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients Methylprednisolone, Isotonic Sodium Chloride - Osteoarthrosis | Phase 2 / Phase 3 | Completed | Copenhagen University Hospital, Rigshospitalet | 64 | 2015-09-01 | 2017-01-18 |
| The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury Omega-3, Vegetation Protein Powder, InflanNox - Neuropathic Pain, Depression | Phase 3 | Completed | Brock University | 20 | 2014-09-01 | 2015-07-30 |
| Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury Midodrine, Placebo - Spinal Cord Injury | Phase 3 | Completed | James J. Peters Veterans Affairs Medical Center | 19 | 2014-03-01 | 2025-02-21 |
| Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA L-Threo DOPS, placebo - Multiple System Atrophy | Phase 2 / Phase 3 | Completed | University Hospital, Toulouse | 107 | 2014-01-21 | 2026-04-08 |
| Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach EGCG as putative neuroprotective agent, Placebo - Multiple System Atrophy | Phase 3 | Completed | Dr. Johannes Levin | 92 | 2014-01-01 | 2024-03-12 |
| The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia Albuterol-sulphate, Ipratropium-bromide, placebo - Familial Dysautonomia | Phase 3 | Completed | NYU Langone Health | 15 | 2013-03-01 | 2016-06-02 |
| Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy Double blinded IVIg, Double blinded Placebo, Single Blinded IVIg - Autoimmune Autonomic Ganglionopathy (AAG) | Phase 2 / Phase 3 | Completed | Beth Israel Deaconess Medical Center | 6 | 2012-02-01 | 2017-07-02 |
| A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease Droxidopa, Placebo - Orthostatic Hypotension, Parkinson's Disease | Phase 3 | Completed | Chelsea Therapeutics | 225 | 2010-06-01 | 2014-05-20 |
| Carbidopa for the Treatment of Nausea and Vomiting in Familial Dysautonomia Carbidopa, Placebo - Familial Dysautonomia | Phase 3 | Completed | NYU Langone Health | 12 | 2009-12-01 | 2016-03-28 |
| A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 263 | 2008-09-01 | 2014-05-16 |
| Peripheral Dopamine in Postural Tachycardia Syndrome Carbidopa, Placebo - Postural Tachycardia Syndrome, Orthostatic Intolerance | Phase 2 / Phase 3 | Completed | Vanderbilt University | 32 | 2008-05-01 | 2022-01-24 |
| Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Droxidopa, Placebo - Neurogenic Orthostatic Hypotension, Non-Diabetic Autonomic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 103 | 2008-01-01 | 2014-05-16 |
| Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) Placebo, Droxidopa - Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy | Phase 3 | Completed | Chelsea Therapeutics | 181 | 2008-01-01 | 2014-05-20 |
Showing 20 of 21. Sign in to see all of them.
Hypotension, Orthostatic (10) · Multiple System Atrophy (8) · Pure Autonomic Failure (5) · Parkinson Disease (4) · Spinal Cord Injuries (4) · Hypotension (3) · dopamine beta hydroxylase deficiency (3) · Dizziness (2) · Dysautonomia, Familial (2) · Orthostatic Intolerance (2) · Parkinsonian Disorders (2) · Postural Orthostatic Tachycardia Syndrome (2) · Asthenia (1) · Autonomic Dysreflexia (1)
Nervous System Diseases (21) · Autonomic Nervous System Diseases (20) · Central Nervous System Diseases (14) · Cardiovascular Diseases (12) · Neurodegenerative Diseases (12) · Orthostatic Intolerance (11) · Vascular Diseases (11) · Basal Ganglia Diseases (10) · Brain Diseases (10) · Movement Disorders (10) · Synucleinopathies (10) · Pathological Conditions, Signs and Symptoms (9) · Hypotension (8) · Neurologic Manifestations (8)
Droxidopa (5) · Carbidopa (2) · Midodrine (2) · Albuterol (1) · Buspirone (1) · Curcumin (1) · Docosahexaenoic Acids (1) · Immunoglobulins, Intravenous (1) · Injections (1) · Iodine-123 (1) · Ipratropium (1) · Ivabradine (1) · Mannitol (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1)
Chelsea Therapeutics (4) · James J. Peters Veterans Affairs Medical Center (2) · NYU Langone Health (2) · Beth Israel Deaconess Medical Center (1) · Biohaven Pharmaceuticals, Inc. (1) · Brock University (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dr. Johannes Levin (1) · GE Healthcare (1) · Theravance Biopharma (1) · US Department of Veterans Affairs (1) · University Hospital, Toulouse (1) · University of California, San Diego (1) · University of Utah (1) · Valenta Pharm JSC (1)
United States (14) · Canada (5) · Australia (3) · France (3) · Germany (3) · New Zealand (3) · Austria (2) · Denmark (2) · Italy (2) · Russia (2) · United Kingdom (2) · Bulgaria (1) · China (1) · Estonia (1) · Hungary (1)
Roy Freeman, MD (2) · Alberto Vasquez, MD (1) · Alfredo J Gamboa, MD (1) · Alvin McElveen, MD (1) · Brent Goodman, MD (1) · Christopher J Mathias, MD (1) · Christopher J. Mathias, MD (1) · David J. Allison, MSc. (1) · David S. Ditor, PhD. (1) · Horacio C Kaufmann, M.D. (1) · Horacio Kaufmann Kaufmann, MD (1) · Horacio Kaufmann, MD (1) · Jill M Wecht, Ed.D (1)
PMID 27538531, PMID 28494751, PMID 17385265, PMID 17951266, PMID 17965289, PMID 19651280, PMID 21062792, PMID 21762873, PMID 22174345, PMID 23700789, PMID 24326693, PMID 25350981, PMID 26241226, PMID 26545369, PMID 29573263, PMID 30003579, PMID 31278067, PMID 32203065, PMID 33177997, PMID 34115419, PMID 35366432, PMID 38712567, PMID 41269291, PMID 42475649
2015 (1), 2018 (1), U54NS065736 (1)